S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts

$1.17
-0.11 (-8.59%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Feb. 29)
-$0.36 Missed By -$0.07
Consensus EPS
(Feb. 29)
-$0.29
Skip Charts & View Estimated and Actual Earnings Data

KPTI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KPTI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Karyopharm Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243($0.37)($0.09)($0.27) 
Q2 20242($0.32)($0.08)($0.20) 
Q3 20243($0.30)($0.06)($0.21) 
Q4 20242($0.24)($0.06)($0.15) 
FY 202410($1.23)($0.29) ($0.83)

KPTI Earnings Date and Information

Karyopharm Therapeutics last announced its quarterly earnings results on February 29th, 2024. The reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The firm had revenue of $33.75 million for the quarter, compared to analysts' expectations of $33.50 million. Karyopharm Therapeutics has generated ($1.25) earnings per share over the last year (($1.25) diluted earnings per share). Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.19) to ($1.05) per share. Karyopharm Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Karyopharm Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
2/29/2024Q4 2023($0.29)($0.36)($0.07)($0.36)$33.50 million$33.75 million    
11/2/2023Q3 2023($0.28)($0.30)($0.02)($0.30)$37.34 million$36.01 million
8/2/2023Q2 2023($0.34)($0.29)+$0.05($0.29)$36.23 million$37.58 million
5/4/2023Q1 2023($0.34)($0.30)+$0.04($0.30)$37.87 million$38.70 million
2/15/2023Q4 2022($0.34)($0.43)($0.09)($0.43)$33.88 million$33.58 million    
11/3/2022Q3 2022($0.56)($0.45)+$0.11($0.45)$34.82 million$36.15 million
8/4/2022Q2 2022($0.63)($0.62)+$0.01($0.62)$36.38 million$39.68 million
5/5/2022Q1 2022($0.63)($0.53)+$0.10($0.53)$34.78 million$47.67 million    
2/8/2022Q4 2021($0.40)$0.46+$0.86$0.46$55.98 million$126.27 million  
11/3/2021Q3 2021($0.68)($0.69)($0.01)($0.69)$25.84 million$37.69 million    
8/5/2021Q2 2021($0.72)($0.71)+$0.01($0.71)$26.86 million$22.60 million    
5/2/2021Q1 2021($0.71)($0.77)($0.06)($0.77)$26.50 million$23.26 million  

Karyopharm Therapeutics Earnings - Frequently Asked Questions

When is Karyopharm Therapeutics's earnings date?

Karyopharm Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on KPTI's earnings history.

Did Karyopharm Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Karyopharm Therapeutics (NASDAQ:KPTI) missed the analysts' consensus estimate of ($0.29) by $0.07 with a reported earnings per share (EPS) of ($0.36). Learn more on analysts' earnings estimate vs. KPTI's actual earnings.

How can I listen to Karyopharm Therapeutics's earnings conference call?

The conference call for Karyopharm Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Karyopharm Therapeutics's conference call transcript?

The conference call transcript for Karyopharm Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Karyopharm Therapeutics generate each year?

Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded annual revenue of $146.03 million.

How much profit does Karyopharm Therapeutics generate each year?

Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded net income of -$143.10 million. KPTI has generated -$1.25 earnings per share over the last four quarters.

What is Karyopharm Therapeutics's EPS forecast for next year?

Karyopharm Therapeutics's earnings are expected to grow from ($1.19) per share to ($1.05) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:KPTI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners